Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelail cells

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 917-924

  Witowski, Janusz ^a   Korybalska, Katarzyna ^a   Ksiazek, Krzysztof ^a   Wiśniewska Elnur, Justyna ^a   Jörres, Achim ^b   Lage, Christina ^c   Schaub, Thomas P ^c   Passlick Deetjen, Jutta ^c   Breborowicz, Andrzej ^a   Grzegorzewska, Alicja ^a   Ksiazek, Andrzej ^d   Liberek, Tomasz ^e   Lichodziejewska Niemierko, Monika ^e   Majdan, Maria ^d   Rutkowski, Bolesław ^e   Stompór, Tomasz ^f   Sułowicz, Władysław ^f  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c FRESENIUS MEDICAL CARE   (Germany)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Biocompatibility; Glucose degradation products; Peritoneal dialysis; Peritoneal mesothelial cells

Indexed keywords

CA 125 ANTIGEN; CYTOKINE; FIBRONECTIN; GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIALYSATE; DIALYSIS MEMBRANE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LONG TERM CARE; MALE; MESOTHELIUM CELL; PERITONEUM CELL; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CELL DIVISION; CELLS, CULTURED; EPITHELIAL CELLS; FEMALE; GLUCOSE; HEMODIALYSIS SOLUTIONS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEUM; RANDOMIZED CONTROLLED TRIALS;

EID: 11144358420     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh013     Document Type: Article

References (20)

1. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
2. Witowski J, Bender TO, Wisniewska-Elnur J et al. Mesothelial toxicity of peritoneal dialysis fluids is primarily related to glucose degradation products, not to glucose per se. Perit Dial Int 2003; 23: 381-390
3. Arbeiter K, Bidmon B, Endemann M et al. Peritoneal dialysate fluid composition determines heat shock protein expression patterns in human mesothelial cells. Kidney Int 2001; 60: 1930-1937
4. Miyata T, Horie K, Ueda Y et al. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-435
5. Stylianou E, Jenner LA, Davies M. Coles GA, Williams JD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990; 37: 1563-1570
6. Yanez-Mo M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413
7. Yen CJ, Fang CC, Chen YM et al. Extracellular matrix proteins modulate human peritoneal mesothelial cell behavior. Nephron 1997; 75: 188-195
8. Zemel D, Koomen GC, Struijk DG, Krediet RT. Fibronectin during CAPD-related peritonitis: No indications for intraperitoneal production. Blood Purif 1993; 11: 378-383
9. Witowski J, Wisniewska J, Korybalska K et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12: 2434-2441
10. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21: 560-567
11. Jones S, Holmes CJ, Krediet RT et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-1538
12. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357
13. Gotloib L, Shostack A, Bar Sella P, Cohen R. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Int 1987; 7: 148-155
14. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27
15. Morgan LW, Wieslander A, Davies M et al. Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration. Kidney Int 2003; 64: 1854-1866
16. Morgan LW, Wieslander A, Williams JD et al. The rate of remesothelialization following in vitro wounding is normalized in low glucose degradation product-containing peritoneal dilaysis solutions and is associated with increased CA125 expression (Abstract). Perit Dial Int 2002; 22: 103
17. Tauer A, Knerr T, Niwa T et al. In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280: 1408-1414
18. Jones S, Johnston J, Do J-Y et al. Low GDP dialysis solution (CAPD Balance) induces less CML formation (on type IV collagen) and is associated with normalized mesothelial proliferation in vitro (Abstract). Perit Dial Int 2002; 22: 102
19. Pecoits-Filho R, Araujo MR, Lindholm B et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480-1486
20. Hurst SM, Wilkinson TS, McLoughlin RM et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705-714